# US 11,439,670 B2 · Akkermansia muciniphila EB-AMDK27 strain and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,439,670 B2 - Document ID: US11439670B2 - Status: Granted - Kind: B2 - Application number: 17/258,510 - Filed: 2020-05-11 - Published: 2022-05-05 - Granted: 2022-09-13 - Earliest claimed: 2019-08-23 - Assignees: Enterobiome Inc. - Applicants: Enterobiome Inc. - Inventors: Jae-Gu Seo; Joo-Hyun Shin; Do-Kyung Lee - Web page: https://patentgrep.com/patent/US11439670B2 ## CPC - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics - A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 3/04: Anorexiants; Antiobesity agents - A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48) - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - C12N 1/205: Bacterial isolates - A23V 2200/00: Function of food ingredients - C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION - C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS ## Abstract Disclosed are a novel Akkermansia muciniphila EB-AMDK27 strain having the effect of preventing or treating inflammatory disease or metabolic disease, and a pharmaceutical composition effective for preventing or treating inflammatory disease or metabolic disease, which contains the strain, a culture thereof, or a dried product thereof. While traditional probiotics generally have insufficient therapeutic effects on inflammatory or metabolic diseases, the disclosed next generation probiotic strain has an excellent effect on the prevention or treatment of inflammatory disease and/or metabolic disease so that it may be used as a new prophylactic and therapeutic tool. ## Claims ### Claim 1 A pharmaceutical composition comprising an isolated Akkermansia muciniphila EB-AMDK27 strain (accession number KCTC 13758BP), a culture thereof, or a dried product thereof; and a pharmaceutically acceptable carrier or an excipient, wherein the Akkermansia muciniphila EB-AMDK27 strain is lyophilized and/or enteric coated. ### Claim 2 (depends on 1) The pharmaceutical composition of claim 1, wherein the isolated Akkermansia muciniphila EB-AMDK27 strain comprises a 16s rRNA gene of SEQ ID NO: 1. ### Claim 3 (depends on 1) The pharmaceutical composition of claim 1, which contains a probiotic form of the strain or a pasteurized form of the isolated Akkermansia muciniphila EB-AMDK27 strain. ### Claim 4 (depends on 1) The pharmaceutical composition of claim 1, which contains, as an active ingredient, the Akkermansia muciniphila EB-AMDK27 strain at a concentration of 108 to 1012 CFU/g of the composition, or a culture containing viable cells or pasteurized cells of the Akkermansia muciniphila EB-AMDK27 strain at a concentration of 108 to 1012 cells/g of the composition. ### Claim 5 A food comprising an isolated Akkermansia muciniphila EB-AMDK27 strain (accession number KCTC 13758BP), a culture thereof, or a dried product thereof and a carrier or an excipient, wherein the Akkermansia muciniphila EB-AMDK27 strain is lyophilized and/or enteric coated. ### Claim 6 A method selected from the following (a)-(f), said method comprising administering to a subject in need thereof an effective amount of a composition which comprises, as an active ingredient, an isolated Akkermansia muciniphila EB-AMDK27 strain (accession number KCTC 13758BP), a culture thereof, a dried powder of the isolated strain, or a dried powder of the culture, (a) preventing or treating gastrointestinal inflammatory disease of the subject; (b) preventing or treating insulin resistance of the subject; (c) preventing or treating dyslipidemia of the subject; (d) reducing cholesterol levels in the subject; (e) reducing body weight of the subject; and (f) increasing secretion of GLP-1 (glucagon like peptide-1) and/or PYY (peptide YY) of the subject. ### Claim 7 (depends on 6) The method of claim 6, wherein the isolated Akkermansia muciniphila EB-AMDK27 strain comprises a 16s rRNA gene of SEQ ID NO: 1. ### Claim 8 (depends on 6) The method of claim 6, wherein the composition comprises a probiotic form of the strain or a pasteurized form of the isolated Akkermansia muciniphila EB-AMDK27 strain. ### Claim 9 (depends on 6) The method of claim 6, wherein the gastrointestinal inflammatory disease is selected from the group consisting of inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, intestinal Behcet's disease, radiation enteritis, and ischemic enteritis. ### Claim 10 (depends on 6) The method of claim 6, wherein the composition comprises, as an active ingredient, the Akkermansia muciniphila EB-AMDK27 strain at a concentration of 108 to 1012 CFU/g of the composition, or a culture containing viable cells or pasteurized cells of the Akkermansia muciniphila EB-AMDK27 strain at a concentration of 108 to 1012 cells/g of the composition.